These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27408930)

  • 21. Delivery of interferon-beta to the monkey nervous system following intranasal administration.
    Thorne RG; Hanson LR; Ross TM; Tung D; Frey WH
    Neuroscience; 2008 Mar; 152(3):785-97. PubMed ID: 18304744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.
    Lubina-Dąbrowska N; Stepień A; Sulkowski G; Dąbrowska-Bouta B; Langfort J; Chalimoniuk M
    Arch Immunol Ther Exp (Warsz); 2017 Aug; 65(4):325-338. PubMed ID: 28299403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.
    Fernández O; Mayorga C; Luque G; Guerrero M; Guerrero R; Leyva L; León A; Blanca M
    J Neurol; 2001 May; 248(5):383-8. PubMed ID: 11437159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
    Jensen J; Krakauer M; Sellebjerg F
    Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line.
    Uitdehaag BM; Hoekstra K; Koper JW; Polman CH; Dijkstra CD
    J Interferon Cytokine Res; 2001 Mar; 21(3):133-5. PubMed ID: 11331035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
    Stojanovic I; Vojinovic S; Ljubisavljevic S; Pavlovic R; Basic J; Pavlovic D; Ilic A; Cvetkovic T; Stukalov M
    J Neurol Sci; 2012 Dec; 323(1-2):187-92. PubMed ID: 23026532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.
    Mintzer RJ; Croze E; Rubanyi GM; Johns A
    J Interferon Cytokine Res; 1998 Nov; 18(11):939-45. PubMed ID: 9858315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effects of recombinant-interferon-beta1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis.
    Maffione AB; Tatò E; Losito S; Nacci C; Mitolo V; Troiano M; Ruggieri M; Livrea P; Jirillo E
    Immunopharmacol Immunotoxicol; 2000 Feb; 22(1):1-18. PubMed ID: 10737253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up.
    Gelati M; Corsini E; Dufour A; Massa G; La Mantia L; Milanese C; Nespolo A; Salmaggi A
    J Neurol; 1999 Jul; 246(7):569-73. PubMed ID: 10463358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
    Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
    J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up.
    Bencsik K; Füvesi J; Fricska-Nagy Z; Rajda C; Losonczi E; Török M; Vécsei L
    J Interferon Cytokine Res; 2006 Feb; 26(2):96-100. PubMed ID: 16487029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
    Skrzipek S; Vogelgesang A; Bröker BM; Dressel A
    Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.
    Deisenhammer F; Reindl M; Berger T
    J Interferon Cytokine Res; 2001 Mar; 21(3):167-71. PubMed ID: 11331039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
    Brochet B; Lemaire G; Beddiaf A;
    Rev Neurol (Paris); 2006 Jun; 162(6-7):735-40. PubMed ID: 16840982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-beta 1b in the treatment of multiple sclerosis.
    Río J; Montalban X
    Expert Opin Pharmacother; 2005 Dec; 6(16):2877-86. PubMed ID: 16318438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.